Updated Financial Calendar for 2022
April 28 2022 - 9:13AM
Updated Financial Calendar for 2022
Orphazyme A/S in
restructuringCompany announcement
No. 22/2022www.orphazyme.comCompany Registration No. 32266355
Copenhagen,
Denmark, April 28,
2022 – Orphazyme A/S in restructuring
(ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage
biopharmaceutical company, announces an update to the Company’s
Financial Calendar for the remainder of 2022 following the current
status of the in-court restructuring proceedings of the Company
(please see company announcements no. 10/2022 and 11/2022).
Deadline for submission of shareholder
proposals to Annual General MeetingNo later than six weeks
prior to the Annual General Meeting 2022
Annual Report 2021May 16,
2022
Annual General Meeting 2022No
later than 1 month after the completion of the ongoing in-court
restructuring proceedings
Interim Report First Half
2022August 25, 2022
For additional information, please
contact
Orphazyme A/S in
restructuring
Anders Vadsholt, Chief Executive Officer and
Chief Financial Officer: +45 2898 9055
John Sommer Schmidt, Restructuring
Administrator: +45 8620 7500
About
OrphazymeOrphazyme is a late-stage
biopharmaceutical company developing arimoclomol for Niemann-Pick
disease type C (NPC). Orphazyme is headquartered in Denmark.
Orphazyme’s shares are listed on Nasdaq Copenhagen (ORPHA).
About
arimoclomolArimoclomol is an investigational drug
candidate that amplifies the production of heat shock proteins
(HSPs). HSPs can rescue defective misfolded proteins and improve
the function of lysosomes. Arimoclomol is administered orally, and
has now been studied in 10 Phase 1, four Phase 2, and three pivotal
Phase 2/3 trials. Arimoclomol has received Orphan Drug Designation
(ODD) for NPC in the US and EU. Arimoclomol has received Fast-Track
Designation (FTD), Breakthrough Therapy Designation (BTD), and Rare
Pediatric Disease Designation (RPDD) from the U.S. Food and Drug
Administration (FDA) for NPC. On June 17, 2021, Orphazyme received
a Complete Response Letter from the FDA regarding its New Drug
Application for arimoclomol for the treatment of NPC. The Company
plans to request a Type C Meeting with the FDA in Q2 2022.
Forward-looking statement This
company announcement may contain certain forward-looking statements
under the U.S. Private Securities Litigation Reform Act of 1995 and
otherwise, including forward-looking statements about the
Company’s intention to file annual and interim reports in
Denmark, and host an annual general meeting, and the timing
thereof. Although the Company believes its expectations are based
on reasonable assumptions, all statements other than statements of
historical fact included in this company announcement about future
events are subject to (i) change without notice and (ii) factors
beyond the Company’s control, including pursuant to regulatory or
judicial intervention. Except as required by law, the Company
assumes no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ
materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future.
- 22-2022 Updated Financial Calendar for 2022
Strategic Partners A/s (LSE:0CUM)
Historical Stock Chart
From Dec 2024 to Jan 2025
Strategic Partners A/s (LSE:0CUM)
Historical Stock Chart
From Jan 2024 to Jan 2025